Evidence map›Paper›PMID 33558639›Full record

ArticleScientific reports2021

Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC).

Vidhi Khanna, Hyunjoon Kim, Wenqiu Zhang, Peter Larson, Manan Shah, Thomas S Griffith, David Ferguson, Jayanth Panyam

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Vidhi KhannaDepartment of Pharmaceutics, University of Minnesota, Minneapolis, USA.
Hyunjoon KimDepartment of Pharmaceutics, University of Minnesota, Minneapolis, USA.
Wenqiu ZhangDepartment of Pharmaceutics, University of Minnesota, Minneapolis, USA.
Peter LarsonDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, USA.
Manan ShahDepartment of Pharmaceutics, University of Minnesota, Minneapolis, USA.
Thomas S GriffithMasonic Cancer Center, University of Minnesota, Minneapolis, USA.
David FergusonDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, USA.
Jayanth PanyamDepartment of Pharmaceutics, University of Minnesota, Minneapolis, USA. jayanth.panyam@temple.edu.ORCID http://orcid.org/0000-0002-8656-2244
University of Minnesota · USTemple University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a significant interest in designing therapeutic agents that can enhance ADCC and thereby improve clinical responses with approved antibodies. We recently reported the combination of an imidazoquinoline-based TLR7/8 agonist (522) with a monoclonal antibody improved ADCC in vitro and in vivo. In the present study, we tested several new small molecule TLR7/8 agonists that induce significantly higher cytokines compared to both the FDA-approved TLR7 agonist, imiquimod, and 522. We evaluated these agonists in combination with monoclonal antibody therapy, with the main goal of enhancing ADCC. Our studies show these TLR7/8 agonists induce robust pro-inflammatory cytokine secretion and activate NK cells. Specifically, we found the agonists 574 and 558 significantly enhanced NK cell-mediated ADCC in vitro as well as enhanced the anti-cancer efficacy of monoclonal antibodies in two different in vivo mouse models. Additionally, we found the agonists were able to stimulate CD8 T cells, likely indicative of an early adaptive immune response.

Indexed as

Neoplasms, ExperimentalA549 CellsAnimalsAntibody-Dependent Cell CytotoxicityAntineoplastic Agents, ImmunologicalCD8-Positive T-LymphocytesHumansImiquimodKiller Cells, NaturalMiceMice, Inbred BALB CMice, NudeToll-Like Receptor 7Toll-Like Receptor 8Xenograft Model Antitumor AssaysAntineoplastic Agents, ImmunologicalImiquimodTLR7 protein, humanTLR8 protein, humanToll-Like Receptor 7Toll-Like Receptor 8

Identifiers

PMID33558639
PMCPMC7870826
OpenAlexW3126416004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.